Lipid nanoparticles - Metvan: reveling a novel way to deliver a vanadium compound to cancer cells XI International Vanadium Symposium

RUIZ, ME; BARAN, EJ; CACICEDO, ML; FERNANDEZ; RM; CASTRO, GR; SCIOLI MONTOTO, S; TORRES-SANCHEZ, E; LEON, IE

Montevideo

Simposio; Simposio; XI International Vanadium Symposium; 2019

Universidad de la República (UdelaR)

Cancer is one of the main causes of mortality worldwide. Common therapy schemes are always based on chemotherapy, radiotherapy and/or surgery. Among chemotherapeutics, vanadium compounds have recently emerged as non-platinum antitumor agents.In this sense, Metvan ([V(IV)O(Me2phen)2(SO4)]) was identified as one of the most promising vanadium anticancer complex. In this work, Metvan compound was encapsulated into well designed and developed nanostructured lipid carriers (NLCs) with the aim of improving its biopharmaceutical profile by means of bioavailability, degradation, solubility and cell up-take. A quality by design approach was performed to find the optimal nanoparticle formulation for Metvan delivery. Results exhibited that the ideal formulation was obtained by using myristyl myristate as the lipid matrix and Pluronic F128 as the stabilizing agent with a mean nanoparticle size of 230.8 ± 3.1 nm and a mean surface charge of -7.9 ± 0.8 mV. The formulation showed an encapsulation efficiency of 80% approximately and a drug sustained release for more than 60 h was observed. The release mechanism of Metvan from the nanoparticles was fitted a Korsmeyer?Peppas model, indicating that the release in significantly dependent on Metvan Fickian diffusion from the nanoparticles. On the other hand, the results showed that the nanoparticles-Metvan system is more effective to decrease cell viability on human osteosarcoma cells (MG-63) than free drug, suggesting a possible different cell internalization pathway and intracellular effect.